Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer

British Journal of Cancer

Volumn 76, Issue 11, 1997, Pages 1494-1499

  Ando, M ^a   Eguchi, K ^b   Shinkai, T ^a   Tamura, T ^c   Ohe, Y ^a   Yamamoto, N ^a   Kurata, T ^a   Kasai, T ^a   Ohmatsu, H ^c   Kubota, K ^a   Sekine, I ^a   Hojo, N ^c   Matsumoto, T ^c   Kodama, T ^a   Kakinuma, R ^c   Nishiwaki, Y ^c   Saijo, N ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Irinotecan; Sequential administration; Topo I and II inhibitors

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC ALKALOID; BILIRUBIN; ETOPOSIDE; IRINOTECAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 9844220291     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.584     Document Type: Article

References (19)

1. Bertrand R, O'Connor PM, Kerrigan D and Pommier Y (1992) Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 28: 743-748
2. Eckardt JR, Burris HA, Rodriguez GA, Fields SM, Rothenherg ML, Moore TD, Smith SC, Ganupathi R, Weiss GR, Johnson RK, Kuhn JG and Von Hoff DD (1993) A phase I study of the topoisomerase I and II inhibitors topotecan (T) and etoposide (E) (abstract). Proc Am Soc Clin Oncol 12: 137
3. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda M, Nakajima S and Taguehi T for the CPT-11 Lung Cancer Study Group (1992) A phase II study of CPT-11, a new derivative of camptothecin. for previously untreated non-small-cell lung cancer. J Clin Oncol 10: 16-20
4. Goto K, Nishiwaki Y, Saijo N, Nakabayashi T, Kawakami Y, Fujita A, Tohise K, Abe S, Suzuki S, Tsuchiya S, Takahashi S, Hayashi I, Noda K, Kuita Y, Matsuda T, Tamura T and Shimoyama M (1995) A phase II study of irinotecan (CPT-11) and etoposide (VP-16) for metastatic non-small cell lung cancer (NSCLC): Japanese Clinical Oncology Group (JCOG) trial (abstract). Proc Am Soc Clin Oncol 14: 362
5. Hande KR (1990) Etoposide pharmacology. Semin Oncol 19. S3-S9
6. Holthus JJM, Van Oort WJ and Pinedo HM (1981) A sensitive high-performance liquid chromatographic method for determination of the anti-neoplastic agents VP16-213 and VM 26 in biological fluids. Anal Chim Acta 130: 23-30
7. Kaneda N and Yokokura T (1990) Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50: 1721-1725
8. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S and Miura Y (1992) Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50: 604-610
9. Karato A, Sasaki Y, Shinaki T, Eguchi K, Tamura T, Ohe Y, Oshita F, Nishio M, Kunikane H, Arioka H, Ohmatsu H, Nakashima H, Shiraishi J and Saijo N (1993) Phase I study of CPT-11 and etoposide in patients with refractory solid tumors. J Clin Oncol 11: 2030-2035
10. Kaufmann SH (1991) Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51: 1129-1136
11. Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T and Okada K (1992) Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 50: 760-766
12. Masuda N, Fukuoka M, Kudoh S, Matsui Y, Takada M, Nakagawa K, Hiroshima T, Tsukada H, Yana T, Yoshikawa A, Kudo A, Matsuua E, Nitta T, Takifuji N, Terakawa K and Negoro S (1994) Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol 12: 1833-1841
13. Pommier Y (1993) DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chem Pharmacol 32: 103-108
14. Schneider E, Hakin F, Noone M, Goldspiel B, Kohler D and Cowan KH (1994) A phase I study of topotecan (a topoisomerase I inhibitor) in combination with doxorubicin (a topoisomerase II inhibitor) (abstract). Proc Am Soc Clin Oncol 13: 157
15. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N, the CPT-11 Gastrointestinal Cancer Study Group (1993) Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11: 909-913
16. Sumiyoshi H, Fujisawa Y, Ohune T, Yamaoka N, Tamura K and Yamakido M (1995) High-performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma. J Chromatogr B 670: 309-316
17. Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K, Narabayashi M, Fukutomi T, Kondo H, Shimoyama M and Suemasu K (1993) Toxicity Grading Criteria of the Japanese Clinical Oncology Group. Jpn J Clin Oncol 23: 250-257
18. Yamaoka K, Tanigawara Y and Nakagawa T (1981) A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobio-Dyn 4: 879-885.
19. World Health Organization (1979) WHO Hand book for reporting results of cancer treatment. WHO offset publication no. 48. World Health Organization: Geneva. Switzerland